Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Variability in HIV-1 partial genomic sequences in Costa Rican patients: analysis with different bioinformatics tools.

Taylor-Castillo L, León-Bratti MP, Solano-Chinchilla A, Herrera-Martínez G, Boza-Cordero R, León B, Luftig RB, Visoná K.

Rev Panam Salud Publica. 2010 Jan;27(1):23-31.

PMID:
20209228
2.

Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes.

Zhong Q, Chinta DM, Pamujula S, Wang H, Yao X, Mandal TK, Luftig RB.

J Nanobiotechnology. 2010 Feb 24;8:6. doi: 10.1186/1477-3155-8-6.

3.
4.

An HIV/AIDS Prophylactic vaccine is possible.

Zhong Q, Luftig RB.

J Immune Based Ther Vaccines. 2007 Dec 19;5:12.

5.

The RING finger ubiquitin ligase RNF125/TRAC-1 down-modulates HIV-1 replication in primary human peripheral blood mononuclear cells.

Shoji-Kawata S, Zhong Q, Kameoka M, Iwabu Y, Sapsutthipas S, Luftig RB, Ikuta K.

Virology. 2007 Nov 10;368(1):191-204. Epub 2007 Jul 23.

6.

Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures.

Taylor-Castillo L, Herrera-Martínez G, León-Bratti MP, Boza R, León-Rodríguez B, Luftig RB, Visoná K.

Rev Inst Med Trop Sao Paulo. 2005 Nov-Dec;47(6):327-31.

PMID:
16553322
7.

HBx M130K and V131I (T-A) mutations in HBV genotype F during a follow-up study in chronic carriers.

León B, Taylor L, Vargas M, Luftig RB, Albertazzi F, Herrero L, Visona K.

Virol J. 2005 Aug 4;2:60.

8.

Amplification and overexpression of prosaposin in prostate cancer.

Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O.

Genes Chromosomes Cancer. 2005 Dec;44(4):351-64.

PMID:
16080200
10.
11.

Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD).

Mohamadzadeh M, Mohamadzadeh H, Brammer M, Sestak K, Luftig RB.

J Immune Based Ther Vaccines. 2004 Aug 2;2(1):8.

12.

Determination of human cytomegalovirus genetic diversity in different patient populations in Costa Rica.

Ahumada-Ruiz S, Taylor-Castillo L, Visoná K, Luftig RB, Herrero-Uribe L.

Rev Inst Med Trop Sao Paulo. 2004 Mar-Apr;46(2):87-92. Epub 2004 May 5.

13.

Oropharyngeal candidiasis in HIV(+) patients may influence the selection of HIV-1 protease variants.

Hickman PJ, Leigh JE, Mera RM, Fidel PL Jr, Luftig RB.

Virus Res. 2002 Aug;87(2):97-106.

PMID:
12191773
14.

Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics.

Prakash O, Mason A, Luftig RB, Bautista AP.

Front Biosci. 2002 Jul 1;7:e286-300. Epub 2002 Jul 1. Review.

PMID:
12086918
15.

Impact of hepatitis B and hepatitis C virus infections in a hematology-oncology unit at a children's hospital in Nicaragua, 1997 to 1999.

Visoná K, Baez F, Taylor L, Berríos R, León B, Pacheco C, Jirón R, Luftig RB, Somarriba MM.

Clin Diagn Lab Immunol. 2002 May;9(3):622-6.

17.

Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Ikuta K, Suzuki S, Horikoshi H, Mukai T, Luftig RB.

Microbiol Mol Biol Rev. 2000 Dec;64(4):725-45. Review.

18.

Fusion of uninfected T-cells occurs with immature HIV-1 protease-mutant, but not morphologically similar protease inhibitor derived particles.

Bahmani MK, Kameoka M, Goto T, Sano K, Luftig RB, Ikuta K.

Virus Res. 2000 Feb;66(2):131-7.

PMID:
10725546
19.
20.

A specific T-cell subset with CD4+/CD38- markers derived from HIV-1 carriers induces apoptosis in healthy donor-derived T-lymphocytes.

Kameoka M, Auwanit W, Suzuki S, Horikoshi H, Khlai-Khlam N, Meguro T, Yamada K, Tanaka Y, Yoshihara K, Luftig RB, Ikuta K.

Virus Res. 1998 Jul;56(1):115-22.

PMID:
9784070
22.

Low response to hepatitis B virus vaccine in Costa Rican health-care workers.

Taylor L, García Z, Herrera G, Luftig RB, Visona KA.

Hepatology. 1998 Feb;27(2):637. No abstract available. Erratum in: Hepatology 1998 Jun;27(6):1750.

PMID:
9462669
23.

Exposure of resting peripheral blood T cells to HIV-1 particles generates CD25+ killer cells in a small subset, leading to induction of apoptosis in bystander cells.

Kameoka M, Suzuki S, Kimura T, Fujinaga K, Auwanit W, Luftig RB, Ikuta K.

Int Immunol. 1997 Oct;9(10):1453-62.

PMID:
9352350
24.

Production of doughnut-shaped, protease-defective particles from a human T cell clone carrying a provirus with specific mutations in the env, pol, vpr, and nef genes.

Bahmani MK, Kameoka M, Nakaya T, Fujinaga K, Zhong Q, Takahashi H, Nakano T, Nakai M, Ueda S, Jones IM, Luftig RB, Ikuta K.

AIDS Res Hum Retroviruses. 1997 Apr 10;13(6):523-6. No abstract available.

PMID:
9100995
25.

The morphology of the immature HIV-1 virion.

Ohagen A, Luftig RB, Reicin AS, Yin L, Ikuta K, Kimura T, Goff SP, Höglund S.

Virology. 1997 Feb 3;228(1):112-4.

27.

Serial passage of human immunodeficiency virus type 1 generates misalignment deletions in non-essential accessory genes.

Nakaya T, Fujinaga K, Doi H, Suzuki S, Takahashi H, Nishino Y, Kishi M, Azuma I, Luftig RB, Ikuta K.

Virus Res. 1996 Dec;46(1-2):139-47.

PMID:
9029786
28.
29.

Evaluation of a pooling method for routine anti-HCV screening of blood donors to lower the cost burden on blood banks in countries under development.

García Z, Taylor L, Ruano A, Pavón L, Ayerdis E, Luftig RB, Visoná KA.

J Med Virol. 1996 Jul;49(3):218-22.

PMID:
8818968
30.

Genetic organization, size, and complete sequence of early region 3 genes of human adenovirus type 41.

Yeh HY, Pieniazek N, Pieniazek D, Luftig RB.

J Virol. 1996 Apr;70(4):2658-63.

31.

Naturally occurring accessory gene mutations lead to persistent human immunodeficiency virus type 1 infection of CD4-positive T cells.

Kishi M, Zheng YH, Bahmani MK, Tokunaga K, Takahashi H, Kakinuma M, Lai PK, Nonoyama M, Luftig RB, Ikuta K.

J Virol. 1995 Dec;69(12):7507-18.

32.

Isolation of bacteriophage infectious for Vibrio vulnificus.

Pelon W, Siebeling RJ, Simonson J, Luftig RB.

Curr Microbiol. 1995 Jun;30(6):331-6.

PMID:
7773100
33.

Human adenovirus type 41 contains two fibers.

Yeh HY, Pieniazek N, Pieniazek D, Gelderblom H, Luftig RB.

Virus Res. 1994 Aug;33(2):179-98.

PMID:
7975882
34.

Viral interactions with the host-cell cytoskeleton: the role of retroviral proteases.

Luftig RB, Lupo LD.

Trends Microbiol. 1994 May;2(5):178-82. Review.

PMID:
8055183
35.

A rapid screening method for biological activity of human immunodeficiency virus proteinase inhibitors by using a recombinant DNA-derived bacterial system.

Sedlácek J, Fábry M, Horejsí M, Brynda J, Luftig RB, Majer P.

Anal Biochem. 1993 Dec;215(2):306-9. No abstract available.

PMID:
8122796
36.

A dominant epitope of HIV-1 protease recognized by hamster monoclonal antibodies.

Croix DA, Yeh HY, Sedlacek J, Luftig RB, Gottlieb PD.

J Acquir Immune Defic Syndr. 1993 Jun;6(6):558-66.

PMID:
8496788
37.
38.

PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains.

Fontenot G, Johnston K, Cohen JC, Gallaher WR, Robinson J, Luftig RB.

Virology. 1992 Sep;190(1):1-10.

PMID:
1529522
39.

Human enteric adenovirus type 41 binding to HEp-2 cells is specific.

Yeh HY, Luftig RB.

Virology. 1991 Jul;183(1):410-4.

PMID:
2053291
40.
41.

Association of HSP70 with the adenovirus type 5 fiber protein in infected HEp-2 cells.

Macejak DG, Luftig RB.

Virology. 1991 Jan;180(1):120-5.

PMID:
1984643
42.

Enteric adenovirus 41 (Tak) requires low serum for growth in human primary cells.

Pieniazek D, Pieniazek NJ, Macejak D, Luftig RB.

Virology. 1990 Sep;178(1):72-80.

PMID:
2143875
43.

Nucleotide sequence of the region coding for 100K and 33K proteins of human enteric adenovirus type 41 (Tak).

Slemenda SB, Pieniazek NJ, Velarde J Jr, Pieniazek D, Luftig RB.

Nucleic Acids Res. 1990 May 25;18(10):3069. No abstract available.

44.

Human enteric adenovirus type 41 (Tak) contains a second fiber protein gene.

Pieniazek NJ, Slemenda SB, Pieniazek D, Velarde J Jr, Luftig RB.

Nucleic Acids Res. 1990 Apr 11;18(7):1901. No abstract available.

45.

Differential growth of human enteric adenovirus 41 (TAK) in continuous cell lines.

Pieniazek D, Pieniazek NJ, Macejak D, Coward J, Rayfield M, Luftig RB.

Virology. 1990 Jan;174(1):239-49.

PMID:
2294640
46.

Retroviral proteinases.

Oroszlan S, Luftig RB.

Curr Top Microbiol Immunol. 1990;157:153-85. Review. No abstract available.

PMID:
2203608
47.

Sequence of human enteric adenovirus type 41 Tak fiber protein gene.

Pieniazek NJ, Slemenda SB, Pieniazek D, Velarde J Jr, Luftig RB.

Nucleic Acids Res. 1989 Nov 25;17(22):9474. No abstract available.

48.

Nucleotide sequence of human enteric adenovirus type 41 hexon-associated protein VIII precursor (pVIII) including the early region E3 promoter.

Pieniazek N, Velarde J Jr, Pieniazek D, Luftig RB.

Nucleic Acids Res. 1989 Jul 11;17(13):5398. No abstract available.

49.

Inhibition of bacterially expressed HIV protease activity determined by an in vitro cleavage assay with MuLV Pr65gag.

Bu M, Oroszlan S, Luftig RB.

AIDS Res Hum Retroviruses. 1989 Jun;5(3):259-68.

PMID:
2543430

Supplemental Content

Loading ...
Support Center